227 related articles for article (PubMed ID: 33032893)
1. Safety and Tolerability of Sacubitril/Valsartan Initiation in Inpatient Versus Outpatient Setting: A Retrospective Real World Study.
Chng BLK; Hon JS; Chan H; Zheng Y; Gao F; Teo LYL; Sim KLD
Heart Lung Circ; 2021 May; 30(5):674-682. PubMed ID: 33032893
[TBL] [Abstract][Full Text] [Related]
2. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
Senni M; Wachter R; Witte KK; Straburzynska-Migaj E; Belohlavek J; Fonseca C; Mueller C; Lonn E; Chakrabarti A; Bao W; Noe A; Schwende H; Butylin D; Pascual-Figal D;
Eur J Heart Fail; 2020 Feb; 22(2):303-312. PubMed ID: 31820537
[TBL] [Abstract][Full Text] [Related]
3. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
[TBL] [Abstract][Full Text] [Related]
4. Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
Witte KK; Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Fonseca C; Lonn E; Noè A; Schwende H; Butylin D; Chiang Y; Pascual-Figal D;
ESC Heart Fail; 2023 Feb; 10(1):80-89. PubMed ID: 36125177
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
[TBL] [Abstract][Full Text] [Related]
6. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
López-Azor JC; Vicent L; Valero-Masa MJ; Esteban-Fernández A; Gómez-Bueno M; Pérez Á; Díez-Villanueva P; De-Juan J; Manuel-Iniesta Á; Bover R; Del Prado S; Martínez-Sellés M
ESC Heart Fail; 2019 Dec; 6(6):1161-1166. PubMed ID: 31701680
[TBL] [Abstract][Full Text] [Related]
7. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
Wachter R; Senni M; Belohlavek J; Straburzynska-Migaj E; Witte KK; Kobalava Z; Fonseca C; Goncalvesova E; Cavusoglu Y; Fernandez A; Chaaban S; Bøhmer E; Pouleur AC; Mueller C; Tribouilloy C; Lonn E; A L Buraiki J; Gniot J; Mozheiko M; Lelonek M; Noè A; Schwende H; Bao W; Butylin D; Pascual-Figal D;
Eur J Heart Fail; 2019 Aug; 21(8):998-1007. PubMed ID: 31134724
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation.
Akerman CC; Beavers JC
J Pharm Pract; 2021 Jun; 34(3):454-458. PubMed ID: 31581926
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
Carnicelli AP; Lippmann SJ; Greene SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
J Card Fail; 2021 Aug; 27(8):826-836. PubMed ID: 34364659
[TBL] [Abstract][Full Text] [Related]
10. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Carnicelli AP; Li Z; Greiner MA; Lippmann SJ; Greene SJ; Mentz RJ; Hardy NC; Blumer V; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
JACC Heart Fail; 2021 Dec; 9(12):876-886. PubMed ID: 34509408
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome.
Fröb EJ; Sindermann JR; Reinecke H; Tuleta I
Adv Clin Exp Med; 2022 May; 31(5):475-487. PubMed ID: 35092651
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.
Rerick L; Elston C; Kester J; Montepara C; Gengler B
J Cardiovasc Pharmacol; 2021 Mar; 77(3):343-348. PubMed ID: 33298737
[TBL] [Abstract][Full Text] [Related]
14. An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.
Antol DD; Casebeer AW; DeClue RW; Stemkowski S; Russo PA
Adv Ther; 2018 Jun; 35(6):785-795. PubMed ID: 29777521
[TBL] [Abstract][Full Text] [Related]
15. Use of sacubitril/valsartan early after CABG.
Nurzhanova M; Musagaliyeva A; Zhakypova R; Senkibayeva D; Rakisheva A
Open Heart; 2024 Jan; 11(1):. PubMed ID: 38238027
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
17. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
Pascual-Figal D; Wachter R; Senni M; Belohlavek J; Noè A; Carr D; Butylin D
ESC Heart Fail; 2018 Apr; 5(2):327-336. PubMed ID: 29239515
[TBL] [Abstract][Full Text] [Related]
19. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
Nordberg Backelin C; Fu M; Ljungman C
ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
[TBL] [Abstract][Full Text] [Related]
20. Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.
Martens P; Lambeets S; Lau CW; Dupont M; Mullens W
Acta Cardiol; 2019 Apr; 74(2):115-122. PubMed ID: 29909743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
